



## Medicaid Fee-for-Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective 1/19/2023, the following changes will be made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:

- **Glumetza** will be **ADDED** to the program

In conformance with State Education Law, which intends patients receive the lower cost drug alternative, brand name drugs included in this program:

- **Do not require ‘Dispense as Written’ (DAW) or ‘Brand Medically Necessary’ on the prescription.**
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

### IMPORTANT BILLING INFORMATION

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of ‘1’; **Pharmacies should submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive a NCPDP reject response of “22” which means missing/invalid DAW code if other DAW codes are submitted. The only exception to this, is DAW code 1 and “*Brand Medically Necessary*” on the prescription.

### List of Brand Name Drugs included in this program (updated 12/27/2022)

Advair Diskus	Depakote Sprinkle	Pradaxa
Alphagan P 0.15%	Epipen, Epipen JR	Rapamune solution
Amitiza	Firvang	Renvela tablet
Apriso	Flovent HFA	Restasis
Azopt	<b>Glumetza</b>	Retin-A cream
Bethkis	Kazano	Symbicort
Cellcept suspension	Kitabis Pak	Tegretol suspension
Ciprodex	Lialda	Tegretol XR
Combigan	Nesina	Trileptal suspension
Concerta	Nexavar	Ventolin HFA
Copaxone 20mg	Nuvaring	Zegerid
Daytrana	Pentasa	

**Drugs in this program may be subject to prior authorization requirements of other pharmacy programs. This list is subject to change.**

